Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Essex Bio-Technology

Market Cap: HK$3.0b

An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.

Everest Medicines

Market Cap: HK$21.3b

A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.

InnoCare Pharma

Market Cap: HK$34.9b

A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.

Sichuan Kelun-Biotech Biopharmaceutical

Market Cap: HK$119.8b

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.

Simcere Pharmaceutical Group

Market Cap: HK$35.2b

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.

Akeso

Market Cap: HK$142.5b

A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.

RemeGen

Market Cap: HK$54.3b

A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.

Innovent Biologics

Market Cap: HK$176.6b

A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.